Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 15.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 227,732 shares of the company’s stock after purchasing an additional 30,834 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Harmony Biosciences were worth $8,947,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Alps Advisors Inc. purchased a new position in Harmony Biosciences during the 3rd quarter valued at about $548,000. Commonwealth Equity Services LLC raised its holdings in shares of Harmony Biosciences by 10.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 23,252 shares of the company’s stock valued at $913,000 after purchasing an additional 2,144 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Harmony Biosciences by 22.0% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 11,089 shares of the company’s stock valued at $435,000 after purchasing an additional 2,000 shares in the last quarter. Signature Equity Partners LLC bought a new stake in shares of Harmony Biosciences in the 3rd quarter valued at about $37,000. Finally, Bridge City Capital LLC lifted its position in shares of Harmony Biosciences by 26.5% in the 3rd quarter. Bridge City Capital LLC now owns 264,739 shares of the company’s stock worth $10,394,000 after purchasing an additional 55,539 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HRMY shares. Deutsche Bank reiterated a “hold” rating and set a $42.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 1st. Wall Street Zen lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, November 8th. UBS Group reissued a “neutral” rating and issued a $37.00 price objective on shares of Harmony Biosciences in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a report on Thursday. Finally, Oppenheimer restated an “outperform” rating on shares of Harmony Biosciences in a report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average price target of $48.00.

View Our Latest Stock Report on Harmony Biosciences

Insider Activity

In other news, insider Kumar Budur sold 35,852 shares of Harmony Biosciences stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider owned 13,115 shares of the company’s stock, valued at $564,600.75. The trade was a 73.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 72,406 shares of company stock valued at $3,108,520. 11.00% of the stock is owned by insiders.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $33.76 on Monday. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.90 and a 1-year high of $43.49. The stock’s 50-day moving average is $38.65 and its 200 day moving average is $34.62. The company has a market cap of $1.98 billion, a P/E ratio of 11.18, a PEG ratio of 0.36 and a beta of 1.00. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.44 and a quick ratio of 3.42.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.28). The company had revenue of $268.92 million during the quarter, compared to analysts’ expectations of $272.05 million. Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. Harmony Biosciences’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.08 EPS. Research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.55 earnings per share for the current fiscal year.

Latest Harmony Biosciences News

Investors following HRMY have been watching these news items:

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.

Read More

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.